Knight Therapeutics Inc.

Thank you. Thank you.

Good morning, ladies and gentlemen. My name is Sylvie, and I will be your operator today. Welcome to Knight Therapeutics' fourth quarter and year-end 2025 results conference call. Before turning the call over to Samira Sakia, President and CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you, questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to ir at knighttx.com or via phone at 514-484-4483. I would like to remind everyone that this call is being recorded today, March 19th, 2026. And I would like to turn the meeting over to your host for today's call, Samira Sakia. Please go ahead.

Thank you, Sylvie. Good morning, everyone, and welcome to Knight Therapeutics' fourth quarter and year-end 2025 conference call. I'm joined on today's call with Amal Khoury, our Chief Business Officer, and Arvind Ujjana, our Chief Financial Officer. I am proud to announce that we have delivered 12 years of consecutive record high revenues since the inception of Knight. In 2025, we delivered record revenues of $452 million, record adjusted EBITDA of $73 million, and record cash flow from operations of $69 million. Our 2025 revenues grew by $87 million, or 24%, compared to the prior year. This increase was driven by our key promoted products, which delivered growth of 12% on a constant currency basis, as well as the incremental revenues from the Paladin and Sumitomo portfolios, which included four growth products, Xcopri, Orgovex, Mifembre, and Envarsis. The sales of these products grew by 68% in the second half of 2025 compared to the first half of the year according to IQVIA. While delivering record results, we strengthened our Canadian infrastructure and portfolio with the addition of multiple mature cash flow generating products, as well as early launch and pipeline products. This positions our Canadian business to be one of Knight's largest contributors to their revenue and profitability within the next two to three years. We also expanded our partnerships with Ahelson, adding Onesit, with and with INSIGHT adding nictinfo and Zainis for Latin America. In addition, we further advanced our pipeline with the regulatory submissions of TAVALIS in Argentina, Crexant in Canada, Mexico, Chile, and Argentina, and Peru, and the supplemental indication of Minjuvi for follicular lymphoma in Brazil, Mexico, and Argentina, and as announced earlier this year, the submission of nictinfo in Brazil. We now have multiple innovative products, namely Crexant, Calgary, Tavalese, Minjuvi, and Nictimbo awaiting regulatory approval in our territories. In addition, we obtained several regulatory approvals across multiple territories, namely Winsor in Canada, Minjuvi for follicular lymphoma in Brazil, and for second-line DLD-CL in Argentina. Pemezir in Brazil and Mexico and Bopocell are generic to in Colombia. Furthermore, to our regulatory approvals, we had multiple launches throughout the year, namely Journey PM, MyFembre, Orgovix, and Xcopri in Canada, Minjuvi in Argentina and Mexico, Hemazir in Brazil and Mexico, as well as Onisit in Brazil and Mexico. As we have been saying, Knight has built a great pipeline of assets. While we continue to grow the portfolio that we acquired, In 2019, we are now executing and growing our pipeline. In 2024, we had three launches with Invexi and Bejuba in Canada, as well as Ninjuvi for second line DLBCL in Brazil. In 2025, we had 10 launches across Canada and Latin America. And as we look forward to 2026, we expect to have at least another 10 launches across our territories. Before I turn the call over to Arvind to cover our financial results, I'll provide an update on our NCIB. During 2025, we purchased 1.1 million shares for $6.4 million. In the first quarter of 2026, we purchased an additional 1.2 million common shares for $7.3 million. Over to you, Arvind.